Diabetes, obesity & metabolism · 2026
Clinical Outcomes for Newly Diagnosed Diabetes Patients in Korea: A National Health Insurance Data.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Samel, Kim Hyun Jung, Kim Hyung Woo, Park Sun-Hee, Han Sang Youb
Аннотация
AIMS: The early clinical impact of type 2 diabetes is not fully understood due to uncertainties surrounding the timing of disease onset. We assessed clinical outcomes in patients newly diagnosed with type 2 diabetes and without preexisting comorbidities, utilising the Korean National Health Insurance Service database.
MATERIALS AND METHODS: We identified patients (20-80 years) newly diagnosed with type 2 diabetes without prior atherosclerotic cardiovascular or kidney disease (eGFR < 60 mL/min/1.73 m2, albuminuria, or relevant ICD codes). Age- and sex-matched controls were selected (1:4). Primary outcomes included ischemic/hemorrhagic stroke, myocardial infarction, heart failure, chronic kidney disease (CKD) progression to eGFR < 60 mL/min/1.73 m2, renal replacement therapy (RRT), and all-cause mortality.
RESULTS: Among 2 164 060 individuals, 432 812 were newly diagnosed with type 2 diabetes. Participants were followed for a median of 5.1 years (IQR 3.3-6.2 years; maximum follow-up 7.6 years). After adjusting for covariates, the risks in the type 2 diabetes group remained significantly elevated compared to the controls: total composite outcome (hazard ratio, HR [95% confidence interval, CI]: 1.67 [1.64-1.70]), non-renal composite outcome (1.57 [1.53-1.60]), renal composite outcome (1.86 [1.82-1.90]), and individual outcomes including ischemic stroke (1.73 [1.66-1.80]), hemorrhagic stroke (1.24 [1.14-1.35]), myocardial infarction (1.84 [1.73-1.95]), heart failure (2.17 [2.08-2.27]), CKD progression (1.47 [1.41-1.53]), RRT (4.17 [3.51-4.95]), and all-cause mortality (1.14 [1.10-1.19]).
CONCLUSIONS: Patients newly diagnosed with type 2 diabetes faced substantially increased risks of cardiovascular, renal complications, and all-cause mortality, despite preserved baseline kidney function. Proactive risk assessments and preventive strategies are needed to mitigate the long-term burden of diabetes-related complications.
MATERIALS AND METHODS: We identified patients (20-80 years) newly diagnosed with type 2 diabetes without prior atherosclerotic cardiovascular or kidney disease (eGFR < 60 mL/min/1.73 m2, albuminuria, or relevant ICD codes). Age- and sex-matched controls were selected (1:4). Primary outcomes included ischemic/hemorrhagic stroke, myocardial infarction, heart failure, chronic kidney disease (CKD) progression to eGFR < 60 mL/min/1.73 m2, renal replacement therapy (RRT), and all-cause mortality.
RESULTS: Among 2 164 060 individuals, 432 812 were newly diagnosed with type 2 diabetes. Participants were followed for a median of 5.1 years (IQR 3.3-6.2 years; maximum follow-up 7.6 years). After adjusting for covariates, the risks in the type 2 diabetes group remained significantly elevated compared to the controls: total composite outcome (hazard ratio, HR [95% confidence interval, CI]: 1.67 [1.64-1.70]), non-renal composite outcome (1.57 [1.53-1.60]), renal composite outcome (1.86 [1.82-1.90]), and individual outcomes including ischemic stroke (1.73 [1.66-1.80]), hemorrhagic stroke (1.24 [1.14-1.35]), myocardial infarction (1.84 [1.73-1.95]), heart failure (2.17 [2.08-2.27]), CKD progression (1.47 [1.41-1.53]), RRT (4.17 [3.51-4.95]), and all-cause mortality (1.14 [1.10-1.19]).
CONCLUSIONS: Patients newly diagnosed with type 2 diabetes faced substantially increased risks of cardiovascular, renal complications, and all-cause mortality, despite preserved baseline kidney function. Proactive risk assessments and preventive strategies are needed to mitigate the long-term burden of diabetes-related complications.